{"id":295304,"date":"2025-08-25T00:00:00","date_gmt":"2025-08-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0045-2024-biopharma-chronic-kidney-disease-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-05-02T23:16:01","modified_gmt":"2026-05-02T23:16:01","slug":"algomd0045-2025-biopharma-chronic-kidney-disease-current-treatment-treatment-algorithms-claims-data-analysis-chronic","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0045-2025-biopharma-chronic-kidney-disease-current-treatment-treatment-algorithms-claims-data-analysis-chronic\/","title":{"rendered":"Chronic Kidney Disease &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Chronic Kidney Disease (US)"},"content":{"rendered":"<p>Chronic kidney disease (<abbr title=\"chronic kidney disease\">CKD<\/abbr>) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The <abbr title=\"chronic kidney disease\">CKD<\/abbr> drug market primarily comprises antihypertensive agents and <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors, which are intended to delay disease progression. <abbr title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors are the standard-of-care therapy for <abbr title=\"chronic kidney disease\">CKD<\/abbr>. <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors, primarily Jardiance and Farxiga, are rapidly becoming the preferred treatments for <abbr title=\"chronic kidney disease\">CKD<\/abbr>, owing to their approval for use in all <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients, regardless of diabetes status. Finerenone (Bayer\u2019s Kerendia), a novel nonsteroidal selective mineralocorticoid receptor antagonist (<abbr title=\"mineralocorticoid receptor antagonist\">MRA<\/abbr>), and semaglutide (Novo Nordisk\u2019s Ozempic), a <abbr title=\"glucagon-like peptide\">GLP<\/abbr>-1 receptor agonist, are both approved for treating diabetic kidney disease. This report provides insights into how the key drug classes for <abbr title=\"chronic kidney disease\">CKD<\/abbr> treatment are used in newly diagnosed and recently treated <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed patients?<\/li>\n<li>How has semaglutide been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients receive drug therapy within 365 of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><b>Geography<\/b><strong>:<\/strong> United States<\/p>\n<p><strong>Real-world data:<\/strong> Patient-level claims data analysis<\/p>\n<p><strong>Key drugs covered:<\/strong> RAAS inhibitors, dapagliflozin, empagliflozin, finerenone, semaglutide<\/p>\n<p><strong>Key analyses:<\/strong> Brand \/ therapy usage across patient sample; Newly diagnosed patient analysis; Treatment initiation and progression; Line of therapy analysis; Combination therapy analysis; Source of business for recently treated patients; Persistency and compliance analysis; Product-level patient flow<\/p>\n<p><strong>Key feature:<\/strong> Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-295304","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-kidney-disease","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295304\/revisions"}],"predecessor-version":[{"id":521229,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295304\/revisions\/521229"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}